Literature DB >> 22699438

Hepatitis E vaccine development: a 14 year odyssey.

Ting Wu1, Shao-Wei Li, Jun Zhang, Mun-Hon Ng, Ning-Shao Xia, Qinjian Zhao.   

Abstract

The first prophylactic vaccine, Hecolin®, against hepatitis E virus (HEV) infection and the HEV associated disease was approved by China's State Food and Drug Administration (SFDA) in December 2011. Key milestones during the 14-year HEV vaccine development are summarized in this commentary.  After years of innovative research the recombinant virus-like particle (VLP) based antigen with virion-like epitopes was successfully produced in E. coli production platform on a commercial scale. Safety and efficacy of this vaccine was demonstrated in a large scale phase III clinical trial.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22699438     DOI： 10.4161/hv.20042

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  31 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Development of new hepatitis E vaccines.

Authors:  Yufeng Cao; Zhenhong Bing; Shiyu Guan; Zecai Zhang; Xinping Wang
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

Review 3.  Hepatitis E virus: An ancient hidden enemy in Latin America.

Authors:  Nora A Fierro; Mauricio Realpe; Tzintli Meraz-Medina; Sonia Roman; Arturo Panduro
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

4.  Hepatitis E infection during pregnancy.

Authors:  Shahnaz A Chaudhry; Natasha Verma; Gideon Koren
Journal:  Can Fam Physician       Date:  2015-07       Impact factor: 3.275

Review 5.  Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design.

Authors:  Rosalynn L Ord; Marilis Rodriguez; Cheryl A Lobo
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.

Authors:  Yue Zhang; Min Li; Fan Yang; Yufang Li; Zizheng Zheng; Xiao Zhang; Qingshan Lin; Ying Wang; Shaowei Li; Ningshao Xia; Jun Zhang; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.

Authors:  Xiaoqing Cheng; Yueyuan Zhao; Xuefeng Zhang; Hui Jin; Jie Min
Journal:  Hum Vaccin Immunother       Date:  2017-04-27       Impact factor: 3.452

Review 8.  Commercializing diarrhea vaccines for travelers.

Authors:  Rosa López-Gigosos; Marina Segura-Moreno; Rosa Díez-Díaz; Elena Plaza; Alberto Mariscal
Journal:  Hum Vaccin Immunother       Date:  2014-02-04       Impact factor: 3.452

9.  Design strategies to address the effect of hydrophobic epitope on stability and in vitro assembly of modular virus-like particle.

Authors:  Alemu Tekewe; Natalie K Connors; Anton P J Middelberg; Linda H L Lua
Journal:  Protein Sci       Date:  2016-06-13       Impact factor: 6.725

10.  Hepatitis E Virus.

Authors:  Georg Pauli; Martin Aepfelbacher; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Barbara Gärtner; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Ruth Offergeld; Uwe Schlenkrich; Volkmar Schottstedt; Rainer Seitz; Johanna Strobel; Hannelore Willkommen; Sally A Baylis
Journal:  Transfus Med Hemother       Date:  2015-06-01       Impact factor: 3.747
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.